Table Graph
   

Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) - versus control - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.44 [0.34, 0.58]< 10%2 studies (1/1)100.0 %NAnot evaluable crucial-
symptomatic Covid-19 0.31 [0.28, 0.35]< 141%6 studies (2/4)100.0 %moderatenot evaluable moderateimportant-
asymptomatic COVID case 0.33 [0.23, 0.48]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
infection (PCR positive symptomatic or not) 0.38 [0.32, 0.45]< 161%3 studies (1/2)100.0 %moderatenot evaluable moderatenon important-
severe COVID-19 occurrence 0.37 [0.06, 2.16]< 10%2 studies (1/1)86.5 %moderatenot evaluable moderatenon important-
transmission (symptomatic confirmed COVID19) 0.52 [0.46, 0.60]< 10%2 studies (-/2)100.0 %seriousnot evaluable lownon important-
vaccine efficacy after dose 1 (and before dose 2) 0.15 [0.04, 0.54]< 159%2 studies (1/1)99.8 %lownot evaluable highnon important-

safety endpoints 00

serious adverse events 0.86 [0.64, 1.17]< 10%1 study (1/-)82.5 %NAnot evaluable important-
adverse events 1.62 [1.54, 1.70]< 10%2 studies (2/-)0.0 %NAnot evaluable non important-
ATE (Myocardial infarction or ischemic stroke) 0.94 [0.87, 1.02]< 173%7 studies (2/5)92.2 %moderatenot evaluable moderatenon important-
ATE with thrombocytopenia 1.57 [0.65, 3.79]< 10%1 study (-/1)15.8 %NAnot evaluable non important-
deep vein thrombosis 1.11 [0.85, 1.44]< 154%3 studies (-/3)21.5 %criticalnot evaluable very lownon important-
Guillain-Barré syndrome 1.26 [0.51, 3.11]< 180%3 studies (1/2)30.7 %NAnot evaluable non important-
immune thrombocytopenia 1.49 [0.84, 2.63]< 175%3 studies (-/3)8.5 %seriousnot evaluable lownon important-
intracranial hemorrhage 1.07 [0.89, 1.29]< 113%6 studies (3/3)23.9 %NAnot evaluable non important-
ischemic stroke 0.92 [0.74, 1.15]< 148%7 studies (3/4)76.3 %seriousnot evaluable lownon important-
Myocardial infarction 1.00 [0.87, 1.16]< 170%8 studies (3/5)48.4 %moderatenot evaluable moderatenon important-
pulmonary embolism 1.28 [1.16, 1.41]< 10%7 studies (3/4)0.0 %seriousnot evaluable lownon important-
serious adverse events (SAE), any 0.87 [0.71, 1.06]< 10%3 studies (3/-)91.6 %NAnot evaluable non important-
splanchnic vein thrombosis (SVT) 1.38 [0.72, 2.65]< 10%1 study (-/1)16.7 %NAnot evaluable non important-
stroke (non-specific, hemorrhagic, and ischemic) 0.99 [0.88, 1.10]< 112%2 studies (-/2)59.1 %criticalnot evaluable very lownon important-
stroke with thrombocytopenia 2.21 [0.99, 4.92]< 10%1 study (-/1)2.6 %NAnot evaluable non important-
thrombocytopenia 1.32 [1.04, 1.68]< 192%3 studies (-/3)1.3 %criticalnot evaluable very lownon important-
venous thromboembolism 1.16 [0.99, 1.36]< 177%6 studies (1/5)3.0 %moderatenot evaluable moderatenon important-
VTE with thrombocytopenia 1.09 [0.52, 2.29]< 10%1 study (-/1)41.0 %NAnot evaluable non important-

AE of interest endpoints 00

cerebral venous sinus thrombosis (CVST) 6.89 [0.82, 57.62]< 192%2 studies (-/2)3.8 %criticalnot evaluable very lowimportant-
Bell's palsy 0.95 [0.77, 1.17]< 145%4 studies (2/2)69.0 %NAnot evaluable non important-
immediate allergic reaction 1.95 [0.07, 58.15]< 10%1 study (1/-)35.2 %NAnot evaluable non important-
multiple sclerosis 1.95 [0.07, 58.15]< 10%1 study (1/-)35.2 %NAnot evaluable non important-
myelitis 1.11 [0.91, 1.35]< 10%3 studies (1/2)14.6 %NAnot evaluable non important-
Potential Immune Gastrointestinal disorders 0.33 [0.03, 3.13]< 10%1 study (1/-)83.3 %NAnot evaluable non important-
Potential Immune Musculoskeletal disorders 0.98 [0.06, 15.60]< 10%1 study (1/-)50.7 %NAnot evaluable non important-
Potential Immune Neuroinflammatory disorders 1.22 [0.33, 4.54]< 10%1 study (1/-)38.4 %NAnot evaluable non important-
Potential Immune Skin disorders 0.73 [0.16, 3.27]< 10%1 study (1/-)65.8 %NAnot evaluable non important-
Potential Immune Vasculitides 0.49 [0.02, 14.54]< 10%1 study (1/-)65.9 %NAnot evaluable non important-
Thromboembolic events 0.49 [0.15, 1.62]< 10%1 study (1/-)87.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons